Cargando…

Sarcoid-Associated Bilateral Multifocal Choroiditis Secondary to Adalimumab

PURPOSE: To report a rare paradoxical development of systemic sarcoidosis in a patient taking adalimumab manifesting as multifocal choroidal infiltrates and seventh nerve palsy. METHODS: This was a single patient case report. RESULTS: A 30-year-old man with a history of psoriatic arthritis on adalim...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkins, Carl Stanley, Ashourian, Kristen Taylor, Sobol, Ethan Kyle, Fink, Matthew, Saltzman, Brian, Teich, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365578/
https://www.ncbi.nlm.nih.gov/pubmed/34409234
http://dx.doi.org/10.4103/2452-2325.312161
Descripción
Sumario:PURPOSE: To report a rare paradoxical development of systemic sarcoidosis in a patient taking adalimumab manifesting as multifocal choroidal infiltrates and seventh nerve palsy. METHODS: This was a single patient case report. RESULTS: A 30-year-old man with a history of psoriatic arthritis on adalimumab presented with intermittent fevers and headaches. Initial infectious serology and initial ophthalmic examination were within normal limits. Over the next month, he developed a seventh nerve palsy, unilateral decreased visual acuity, and bilateral multifocal choroidal infiltrates. The patient was diagnosed with systemic sarcoidosis secondary to tumor necrosis factor alpha (TNFα) inhibitor use after a hilar lymph node biopsy. Upon treatment with high-dose oral corticosteroids, the patient's symptoms and choroidal lesions significantly improved. CONCLUSION: This case report illustrates a rare presentation of ocular, neurologic, and systemic sarcoidosis presenting as a bilateral multifocal choroiditis and seventh nerve paresis in a patient treated with adalimumab. We highlight the importance of obtaining an ophthalmic evaluation in the management of this rare adverse effect of TNFα inhibitors.